PARP inhibitors. PARP inhibitors (PARPis), which inhibit PARP1 as well as other PARP family members153, are FDA approved for high-grade serous ovarian cancer, germlineBRCA1/2-mutated breast cancer, andBRCA1/2-mutated castration-resistant prostate cancer154–158. The gene discussed is PARP1; the disease is ovarian serous adenocarcinoma.